A new drug combo recently approved by the Food & Drug Administration can halt lung cancer in its treacherous tracks — for ...
First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended ...
Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable ...
What’s more, AM-101 improved radiation treatment, slowing down the growth of NSCLC subcutaneous xenograft tumors in mice, by ...
In another positive development for the lung cancer community, NICE has also given its blessing to NHS use of MSD's $25 ...
Research shows regular physical activity can significantly improve quality of life for lung cancer patients. This includes ...
There are no approved therapies to tackle c-Met protein overexpression, AbbVie said in a press release. C-Met is a receptor ...
NovoCure’s Optune Lua, a wearable indicated for patients with metastatic non-small cell lung cancer has received approval ...
For the first time, the National Institute for Health and Care Excellence has recommended a targeted treatment option for ALK-positive non-small-cell lung cancer, to be given after surgery to reduce ...
When I was diagnosed with lung cancer, I didn’t want to receive chemotherapy, especially when I was a good candidate for ...
"Survival rates for lung cancer are still very low compared with other types of the disease and so to see such positive ...